Table 3.

Associations of Baseline Tissue Factor Pathway Inhibitor and Activated Protein C Resistance with Ischemic Stroke Risk by Treatment Assignment

	Odds Ratio per SD Increase (95% Confidence Interval)*
	Estrogen Trial				Estrogen + Progestin Trial
	CEE		CEE Placebo		CEE+MPA		CEE+MPA Placebo		P Value for Interaction†
	N	OR (CI)	N	OR (CI)	N	OR (CI)	N	OR (CI)
Total TFPI, ng/mL	264	1.16 (0.88, 1.52)	248	1.00 (0.75, 1.33)	236	1.13 (0.84, 1.49)	198	1.01 (0.72, 1.41)	0.408
Free TFPI, ng/mL	264	1.55 (1.15, 2.08)	248	1.21 (0.91, 1.60)	236	0.81 (0.59, 1.12)	198	1.16 (0.82, 1.63)	0.861
TFPI Activity, %	263	0.93 (0.71, 1.21)	248	0.91 (0.68, 1.22)	236	1.23 (0.92, 1.65)	198	1.18 (0.87, 1.61)	0.946
nAPCsr, ratio	216	1.02 (0.74, 1.39)	201	0.79 (0.58, 1.07)	208	0.99 (0.72, 1.37)	177	0.78 (0.55, 1.10)	0.134

^*From logistic regression models adjusted for age, race, BMI, waist-hip ratio, smoking, alcohol use, physical activity, diabetes mellitus, prevalent cardiovascular disease (including atrial fibrillation), systolic and diastolic blood pressure, LVH on EKG, use of antihypertensive medications, aspirin, statins, and ever treated for high cholesterol.

^†P values for the interaction in combined trials of active treatment/placebo X biomarker on ischemic stroke risk based on a 1-df test for biomarkers. Covariate adjustment for hysterectomy status and as in the preceding footnote.